100% efficacy to ombitasvir/paritaprevir/ritonavir (± dasabuvir) with or without ribavirin in hepatitis C virus genotypes 1 and 4-infected hemodialysis patients

被引：0
|
作者：
Sanai, F. M. [1 ,2 ]
Alghamdi, A. S. [3 ]
Afghani, A. [4 ]
Alswat, K. A. [5 ]
Aseeri, A. [6 ]
Babatin, M. A. [3 ]
机构：
[1] King Abdul Aziz Med City, Dept Med, Gastroenterol Unit, Jeddah, Saudi Arabia
[2] King Saud Univ, Liver Dis Res Ctr, Riyadh, Saudi Arabia
[3] King Fahad Hosp, Dept Med, Gastroenterol Unit, Jeddah, Saudi Arabia
[4] King Fahad Hosp, Dept Med, Gastroenterol Unit, Madinah Al Munawarrah, Saudi Arabia
[5] King Saud Univ, Liver Dis Res Ctr, Dept Med, Gastroenterol Unit, Riyadh, Saudi Arabia
[6] King Fahd Med City, Riyadh, Saudi Arabia
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)30944-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-277
引用
收藏
页码：S312 / S312
页数：1
相关论文
共 50 条
  • [31] Ombitasvir/paritaprevir/ritonavir plus dasabuvir plus ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV)
    Isakov, Vasily
    Paduta, Dzmitry
    Viani, Rolando M.
    Enejosa, Jeffrey V.
    Pasechnikov, Viktor
    Znoyko, Olga
    Ogurtsov, Pavel
    Bogomolov, Pavel O.
    Maevskaya, Marina V.
    Chen, Xiaotian
    Shulman, Nancy S.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (09) : 1073 - 1076
  • [32] Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir
    Schnell, G.
    Tripathi, R.
    Beyer, J.
    Reisch, T.
    Krishnan, P.
    Dekhtyar, T.
    Irvin, M.
    Hall, C.
    Yu, Y.
    Mobashery, N.
    Redman, R.
    Pilot-Matias, T.
    Collins, C.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 (09) : 1078 - 1088
  • [33] Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1 A Randomized Trial
    Sulkowski, Mark S.
    Eron, Joseph J.
    Wyles, David
    Trinh, Roger
    Lalezari, Jay
    Wang, Chia
    Slim, Jihad
    Bhatti, Laveeza
    Gathe, Joseph
    Ruane, Peter J.
    Elion, Richard
    Bredeek, Fritz
    Brennan, Robert
    Blick, Gary
    Khatri, Amit
    Gibbons, Krystal
    Hu, Yiran B.
    Fredrick, Linda
    Schnell, Gretja
    Pilot-Matias, Tami
    Tripathi, Rakesh
    Da Silva-Tillmann, Barbara
    McGovern, Barbara
    Campbell, Andrew L.
    Podsadecki, Thomas
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (12): : 1223 - 1231
  • [34] Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports
    Ponziani, Francesca Romana
    Siciliano, Massimo
    Lionetti, Raffaella
    Pasquazzi, Caterina
    Gianserra, Laura
    D'Offizi, Gianpiero
    Gasbarrini, Antonio
    Pompili, Maurizio
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2017, 70 (02) : 297 - 300
  • [35] Treatment of Chronic Hepatitis C Genotype 4-infected Patients with Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin: Real Life Data From Saudi Arabia
    Alswat, Khalid A.
    Babatin, Mohamed A.
    Abdelrahman, Awny A.
    Al-Hamoudi, Waleed K.
    Alghamdi, Abdullah S.
    Abdo, Ayman
    Sanai, Faisal M.
    HEPATOLOGY, 2016, 64 : 974A - 975A
  • [36] Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
    Liu, Chen-Hua
    Liu, Chun-Jen
    Su, Tung-Hung
    Yang, Hung-Chih
    Hong, Chun-Ming
    Tseng, Tai-Chung
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (03) : 710 - 717
  • [37] Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials
    Mensing, Sven
    Eckert, Doerthe
    Sharma, Shringi
    Polepally, Akshanth R.
    Khatri, Amit
    Podsadecki, Thomas J.
    Awni, Walid M.
    Menon, Rajeev M.
    Dutta, Sandeep
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (03) : 527 - 539
  • [38] Real-life data on the efficacy and safety of ombitasvir/paritaprevir//ritonavir plus dasabuvir plus ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia
    Babic, Jasmina Simonovic
    Bojovic, Ksenija
    Fabri, Milotka
    Cvejic, Tatjana
    Svorcan, Petar
    Nozic, Darko
    Jovanovic, Maja
    Skrbic, Ranko
    Stojiljkovic, Milos P.
    Mijailovic, Zeljko
    VOJNOSANITETSKI PREGLED, 2019, 76 (05) : 531 - 536
  • [39] Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study
    Flisiak, R.
    Janczewska, E.
    Wawrzynowicz-Syczewska, M.
    Jaroszewicz, J.
    Zarebska-Michaluk, D.
    Nazzal, K.
    Bolewska, B.
    Bialkowska, J.
    Berak, H.
    Fleischer-Stepniewska, K.
    Tomasiewicz, K.
    Karwowska, K.
    Rostkowska, K.
    Piekarska, A.
    Tronina, O.
    Madej, G.
    Garlicki, A.
    Lucejko, M.
    Pisula, A.
    Karpinska, E.
    Kryczka, W.
    Wiercinska-Drapalo, A.
    Mozer-Lisewska, I.
    Jablkowski, M.
    Horban, A.
    Knysz, B.
    Tudrujek, M.
    Halota, W.
    Simon, K.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (09) : 946 - 956
  • [40] Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents
    Shiffman, Mitchell L.
    Rustgi, Vinod
    Bennett, Michael
    Forns, Xavier
    Asselah, Tarik
    Vila, Ramon Planas
    Liu, Li
    Pedrosa, Marcos
    Moller, Jonathan
    Reau, Nancy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (06) : 845 - 851
12345